Analysis of p53 gene mutations in acute myeloid leukemia

D Trecca1, L Longo, A Biondi

  • 1Laboratorio di Ematologia Sperimentale e Genetica Molecolare, Università di Milano, Ospedale Maggiore, Italy.

Insights

p53 gene mutations are rare in acute myeloid leukemia (AML) across various French-American-British (FAB) types. Analysis revealed mutations in only 5 of 70 AML cases, suggesting a recessive role in leukemogenesis.

Area of Science:

  • Molecular Biology
  • Oncology
  • Hematology

Background:

  • Previous studies indicated no p53 gene mutations in acute promyelocytic leukemia (APL, M3 FAB type).
  • The role of p53 mutations in other subtypes of acute myeloid leukemia (AML) remained largely uncharacterized.

Purpose of the Study:

  • To investigate the frequency and spectrum of p53 gene mutations in a broader range of AML subtypes beyond APL.
  • To further elucidate the mechanism of p53 inactivation in AML pathogenesis.

Main Methods:

  • Polymerase chain reaction (PCR) amplification of p53 exons 5-9.
  • Single-strand conformation polymorphism (SSCP) analysis.
  • Direct sequencing of PCR products to identify mutations.

Main Results:

  • Mutant p53 alleles were detected in 5 out of 70 AML cases (M1, M2, M4, M5, M6 FAB types).
  • Mutations included point mutations (amino acid substitutions) and one deletion, affecting exons 5, 6, and 7.
  • Loss of the normal p53 allele was observed in four cases, supporting a recessive inactivation mechanism.

Conclusions:

  • p53 gene mutations occur infrequently in AML across diverse FAB subtypes.
  • These findings reinforce the concept of p53 acting as a tumor suppressor through a two-hit recessive mechanism in leukemogenesis.